Renal/Urology · PANCE / PANRE

Acute Tubular Necrosis (ATN)

Most common cause of intrinsic AKI; tubular epithelial injury from ischemia or nephrotoxins.

Also known as: ATN, acute tubular necrosis, ischemic ATN, nephrotoxic ATN

Overview

Intrinsic AKI characterized by injury and necrosis of renal tubular epithelial cells, most often from ischemic insult (prolonged hypoperfusion) or direct nephrotoxic exposure. The most common cause of hospital-acquired AKI.

Epidemiology

Accounts for ~50% of hospital-acquired AKI and ~75% of AKI in critically ill patients. Mortality 40-60% in ICU patients requiring RRT.

Try two board-style Acute Tubular Necrosis questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1RenalMedium
A 70-year-old man with hypertension is admitted for gastrointestinal bleeding. Lisinopril was started 2 weeks ago, and his baseline serum creatinine is 0.9 mg/dL. His systolic blood pressure stays between 75 and 85 mm Hg for 6 hours before transfusion restores it, and he undergoes contrast CT angiography to localize the bleeding. The next day he develops oliguria. Urinalysis shows muddy brown granular casts. Which of the following is the strongest risk factor for this condition?
  • ARecent intravenous contrast exposure
  • BProlonged renal ischemia from shock
  • CHypertensive nephrosclerosis
  • DBilateral renal artery stenosis
  • ENew angiotensin inhibitor therapy
Reveal answer & full explanation
Correct answer: B — Prolonged renal ischemia from shock
  • ARecent intravenous contrast exposure
  • BProlonged renal ischemia from shock✓
  • CHypertensive nephrosclerosis
  • DBilateral renal artery stenosis
  • ENew angiotensin inhibitor therapy

Why Prolonged renal ischemia from shock is correct

  • Muddy brown granular casts indicate acute tubular necrosis, and sustained hypotension from GI hemorrhage is a direct ischemic cause.
  • Prolonged hypoperfusion injures the metabolically active proximal tubular cells, which slough into the lumen and form the casts.
  • In this vignette the documented shock state is the strongest and most proximate precipitant of the tubular injury.

Why the others are wrong

  • New angiotensin inhibitor therapy — Prerenal-confusion trap: ACE inhibitors drop GFR hemodynamically but do not by themselves produce muddy brown casts of established tubular necrosis.
  • Bilateral renal artery stenosis — Anchoring trap: stenosis predisposes to ACE-inhibitor-induced prerenal failure, not the ischemic ATN driven here by hemorrhagic shock.
  • Recent intravenous contrast exposure — Right-disease-wrong-weight trap: he did receive IV contrast for the CT angiogram, but with normal baseline kidney function the risk of contrast-associated AKI is low, whereas 6 hours of systolic pressure at 75 to 85 mm Hg is a far stronger ischemic insult.
  • Hypertensive nephrosclerosis — Chronic-background trap: underlying hypertensive kidney disease does reduce renal reserve and raises the risk of tubular injury, but his baseline creatinine of 0.9 mg/dL suggests preserved kidney function, and 6 hours of systolic pressure at 75 to 85 mm Hg is the direct ischemic insult that produced the casts.
Question 2RenalMedium
A hospitalized patient develops acute kidney injury after prolonged hypotension. Urine microscopy shows muddy brown granular casts. Which of the following is the most appropriate management?
  • AUrgent initiation of hemodialysis
  • BSupportive care and treat the cause
  • CLow-dose renal dopamine infusion
  • DScheduled intravenous loop diuretic
  • EImmediate high-dose corticosteroids
Reveal answer & full explanation
Correct answer: B — Supportive care and treat the cause
  • AUrgent initiation of hemodialysis
  • BSupportive care and treat the cause✓
  • CLow-dose renal dopamine infusion
  • DScheduled intravenous loop diuretic
  • EImmediate high-dose corticosteroids

Why Supportive care and treat the cause is correct

  • Muddy brown granular casts after hypotension indicate ischemic acute tubular necrosis.
  • Management is supportive: restore perfusion, remove nephrotoxins, and correct volume and electrolytes while tubules recover.
  • Most ischemic ATN improves over days to weeks with these measures alone.

Why the others are wrong

  • Immediate high-dose corticosteroids — steroids treat allergic interstitial nephritis or certain glomerulonephritides, not ischemic tubular injury; this is the wrong-mechanism trap.
  • Low-dose renal dopamine infusion — so-called renal-dose dopamine may transiently raise urine output but does not prevent dialysis, speed recovery, or reduce mortality in ATN, and it can provoke arrhythmias; KDIGO recommends against it; this is the outdated-therapy trap.
  • Urgent initiation of hemodialysis — dialysis is reserved for refractory hyperkalemia, acidosis, volume overload, or uremia, none stated here; this is the overtreatment trap.
  • Scheduled intravenous loop diuretic — a loop diuretic can raise urine output in some patients with ATN, which makes it feel like treatment, but it does not speed tubular recovery, reduce the need for dialysis, or lower mortality, and it can worsen volume depletion; KDIGO advises against diuretics to treat AKI except to manage volume overload, which is not described here; this is the treat-the-urine-output trap.

That's 2. Get 7,700+ more.

Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial →
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Acute Tubular Necrosis (ATN) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Ischemic: sepsis, hemorrhage, prolonged hypotension, cardiac/aortic surgery
  • Nephrotoxic medications: aminoglycosides (gentamicin, tobramycin, amikacin), vancomycin, amphotericin B, cisplatin, foscarnet
  • IV iodinated contrast: clinically meaningful risk mainly with eGFR <30 or existing AKI (ACR-NKF 2020); risk is low when baseline kidney function is normal
  • Endogenous toxins: myoglobin (rhabdomyolysis), hemoglobin (hemolysis), uric acid (tumor lysis), light chains (myeloma)
  • Underlying CKD, advanced age, volume depletion
  • Hemodynamic drug combinations: NSAIDs plus ACEi/ARB with or without a diuretic (triple whammy), especially in elderly or volume-depleted patients

Pathophysiology

Ischemic or toxic injury depletes tubular ATP, disrupts apical brush borders, and causes epithelial cell death and desquamation. Sloughed cells obstruct the tubular lumen → backleak of filtrate, tubuloglomerular feedback, and reduced GFR. Three phases: initiation (hours-days), maintenance (days-weeks of established oliguric AKI), and recovery (polyuric phase as tubules regenerate).

Clinical presentation

Symptoms

  • Often asymptomatic AKI discovered on labs in ICU or postoperative setting
  • Oliguria or anuria common; nonoliguric ATN in 30-50% (better prognosis)
  • Symptoms of underlying cause: sepsis, shock, recent surgery, exposure to nephrotoxin
  • Uremic symptoms if severe: nausea, confusion, dyspnea

Signs / physical exam

  • Volume status variable — euvolemic, overloaded, or depleted depending on cause and management
  • Findings of underlying critical illness
  • Skin findings in atheroemboli (livedo, blue toes)
  • Bladder not distended; no obstruction

Classic findings

Muddy brown granular casts with renal tubular epithelial cells in the urine sediment are the characteristic, highly suggestive finding of ATN (not pathognomonic, and absent in some cases).

Differential diagnosis

  • Prerenal AKI — BUN:Cr >20:1, FENa <1%, bland sediment; responsive to volume — distinguish before fluid challenge
  • Acute interstitial nephritis — Drug exposure (PPI, NSAID, beta-lactam), fever, rash, eosinophilia, WBC casts
  • Glomerulonephritis — Dysmorphic RBCs, RBC casts, proteinuria, hypertension — biopsy-driven diagnosis
  • Postrenal obstruction — Hydronephrosis on US, distended bladder, anuria; rapid reversal with drainage
  • Renal atheroembolic disease — Days-weeks after vascular procedure; livedo reticularis, blue toes, eosinophilia, eosinophiluria
  • Contrast-induced nephropathy — Cr rise within 24-72 h of IV contrast; typically resolves by day 7-10

Diagnostic workup

Diagnostic criteria

Clinical diagnosis: AKI meeting KDIGO criteria with characteristic sediment (muddy brown casts), FENa >2%, recent ischemic or nephrotoxic event, and exclusion of prerenal/postrenal/other intrinsic causes. Biopsy rarely needed.

Labs

  • BMP — rise in creatinine and BUN, often with hyperkalemia, acidosis
  • Urinalysis with microscopy — muddy brown granular casts, renal tubular epithelial cells, FENa >2%
  • Urine sodium >40 mEq/L, urine osmolality <350 (isosthenuria — inability to concentrate)
  • CK if rhabdomyolysis suspected; LDH and haptoglobin if hemolysis suspected
  • SPEP/UPEP with free light chains if multiple myeloma suspected

Imaging

  • Renal ultrasound to exclude obstruction; kidneys typically normal-sized and echotexture
  • CT only if specific cause suspected (atheroembolic disease, masses)

Diagnostic algorithm

PhaseDurationFeaturesManagement Priority
InitiationHours-daysReversible injury; Cr risingIdentify cause; remove nephrotoxin; optimize perfusion
Maintenance1-3 weeksEstablished AKI; oliguria; peak CrSupportive care; RRT if AEIOU criteria; avoid further insults
RecoveryDays-weeksPolyuria; tubular regenerationReplace losses; monitor K, Mg, PO4; gradual return of function
Three phases of acute tubular necrosis with management priorities at each stage.

Treatment

First-line

  • Remove or treat underlying cause: stop offending nephrotoxin, treat sepsis, restore perfusion
  • Optimize hemodynamics: target MAP ≥65 with isotonic crystalloid and vasopressors (norepinephrine first-line) as needed
  • Adjust renally cleared medications (vancomycin, gabapentin, opioids, DOACs)
  • Avoid further insults: NSAIDs, ACEi/ARB during acute phase, iodinated contrast, aminoglycosides
  • Conservative management — no specific therapy reverses established ATN; focus is supportive while tubules regenerate

Second-line / adjunct

  • Loop diuretic — furosemide, bumetanide — for volume overload only; does not change ATN course or improve mortality
  • Renal replacement therapy for KDIGO indications (AEIOU): refractory acidosis, hyperkalemia, ingestion of dialyzable toxin, volume overload, uremic complications
  • Modality choice: CRRT preferred in hemodynamically unstable ICU patients; intermittent HD in stable patients
  • Nutrition support: avoid protein restriction (associated with worse outcomes)
  • During recovery (polyuric phase): replace urinary losses; monitor for hypokalemia, hypomagnesemia, hypophosphatemia

Complications

  • Volume overload, pulmonary edema
  • Hyperkalemia with cardiac arrhythmia
  • Metabolic acidosis (high anion gap from retained acids)
  • Uremic complications: pericarditis, encephalopathy, bleeding
  • Failure to recover, transition to CKD/ESRD (~25% of severe ATN)
  • Death — especially in septic ATN (40-60% in ICU)

PANCE pearls

  • Muddy brown granular casts + renal tubular epithelial cells = ATN sediment.
  • Three phases: initiation (insult), maintenance (oliguria, peak Cr, 1-3 weeks), recovery (polyuria, watch electrolytes).
  • Diuretics do not change outcome but help volume management. 'Furosemide stress test' (no response to 1-1.5 mg/kg) predicts severe AKI.
  • Nonoliguric ATN has better prognosis than oliguric.
  • No medication has been shown to reverse or shorten ATN. Dopamine, fenoldopam, mannitol, and 'renal-dose' dopamine are not recommended.

References

  • KDIGO 2012 — KDIGO Clinical Practice Guideline for Acute Kidney Injury
  • ADQI — Acute Disease Quality Initiative consensus statements on AKI biomarkers and management
  • ACR-NKF 2020 — Davenport MS, et al. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294(3):660-668.

Practice Renal/Urology questions on FirstPassPA

Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start your 7-day free trial → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.